Nuvilex's Medical Marijuana Segment Could Mirror Israel's Success

SOURCE: Goldman Small Cap Research, Inc.

BALTIMORE, MD--(Marketwired - Jul 31, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that considering the success of some of the programs in Israel in treating cancer patients with cannabis, Nuvilex Inc.'s (OTCQB: NVLX) subsidiary, Medical Marijuana Sciences, Inc. may elect to emulate some of that country's initiatives.

In Israel, the medical-marijuana industry has flourished. Today, medical marijuana is prescribed to 11,000 patients, up from 1,800 in 2009, according to the Israeli Health Ministry. It is used to treat an extensive list of illnesses including cancer, Parkinson's, Tourette syndrome, and Post-Traumatic Stress Disorder (PTSD). Importantly, while some cancer patients do smoke medical marijuana, in most cases, the drug is delivered via pill, liquid, food and even vapor. These delivery method alternatives are a bit broader than what is typically found in the U.S.

Perhaps the reason for the forward-thinking of Israeli scientists is the long history of medical marijuana research in Israel, which according to a recent article in Tablet magazine, traces its roots to nearly 50 years ago.

Much like in the U.S., despite the presence of tetrahydrocannabinol (THC) inherent in cannabis that is responsible for the "high," Israeli researchers prefer to remove the THC and raise the concentration of the non-psychoactive cannabidiol, or CBD, which has documented anti-inflammatory and antioxidant properties. In fact, in the 1960's, Israel was a world leader in research on marijuana and its components conducted under the so-called grandfather of cannabis, professor Raphael Mechoulam of Hebrew University, who first isolated the THC component.

Going forward, as Americans continue to embrace the use of marijuana for its medicinal properties coupled with the elimination of THC from cannabis "extracts" and a concentration on the use of CBD as a therapeutic agent, Nuvilex's choice of developing CBD-based treatments for serious cancers becomes validated. Furthermore, a combination therapy for pancreatic cancer that combines a CBD-based treatment with its high profile live-cell encapsulation-based treatment for that disease may well be in Nuvilex's future.

Since the summertime is also a vacation period for the country's legislators, the medical marijuana space has been a bit quiet of late. However, once legislatures return to session, it is likely that this industry segment will enjoy accelerated opportunities.

To view Nuvilex reports and articles and to view our disclaimer, please visit
www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information, visit www.nuvilex.com.

Source: http://www.marketwire.com/mw/release.do?id=1816339&sourceType=3

Dick Morris Daily Show provisional ballot rush limbaugh rush limbaugh karl rove Election 2012 Results